Labcorp warns of danger from steep CMS payment cuts and backs the RESULTS Act
Labcorp Holdings Inc. said CMS payment rates based on inaccurate data could lead to sharp annual cuts that threaten patient access to laboratory services, reaffirmed support for the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, and said it continues to evaluate the impact of these rates on its 2027 financial guidance.
Key points
- The company believes current CMS payment rates rely on data that do not fully represent the commercial laboratory market and could trigger steep annual cuts that endanger patient access to lab services.
- If CMS implements the proposed steep payment cuts, Labcorp’s revenue could fall because part of reimbursement for lab services would be lower, putting pressure on the company’s operating margin.
- If the RESULTS Act is enacted, it could provide sustainable and innovative updates to the laboratory payment system, helping avoid steep cuts and supporting stable Labcorp revenue.
What happened
The company believes current CMS payment rates rely on data that do not fully represent the commercial laboratory market and could trigger steep annual cuts that endanger patient access to lab services. Labcorp also reaffirmed support for the bipartisan RESULTS legislative proposal aimed at creating a sustainable and innovative laboratory testing system, and said it continues to assess the impact of these rates on its 2027 financial guidance.
Why it matters
If CMS implements the proposed steep payment cuts, Labcorp’s revenue could fall because part of reimbursement for lab services would be lower, putting pressure on the company’s operating margin.
When it could help
If the RESULTS Act is enacted, it could provide sustainable and innovative updates to the laboratory payment system, helping avoid steep cuts and supporting stable Labcorp revenue.
Risks and unknown factors
The exact size of the proposed rate cuts is not disclosed, making it hard to gauge impact on revenue and profitability. Moreover, the assessment of the impact on 2027 financial guidance will remain uncertain until additional data are released in February 2027.
What to watch
Watch for the official CMS decision on final payment rates for clinical laboratory services, as that will determine whether steep cuts are implemented.
Financial results for the third quarter of 2026, to be released on October 28, 2026, will allow assessment of revenue and margin dynamics before the 2027 guidance announcement.
Official 2027 financial guidance, planned for release in February 2027, will show how the company expects new CMS rates to affect its performance.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Labcorp
A notification in your browser or on your phone when we publish about Labcorp. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
